Upcoming Conferences:
Anti-Cancer Biopharmaceutical
Power Solutions
Anti-Cancer Biopharmaceutical
September 18 & 19, 2000
The Westin St. Francis
San Francisco
The global anti-cancer therapy market, valued at about $16 billion today, is poised to undergo rapid expansion, doubling, we believe, in four years. Newer, more effective and safer therapies are the primary drivers of this expansion. The old paradigm of cancer therapy--cut (surgery), burn (radiation) and poison (chemotherapy)--is being replaced by less cut (minimal surgery), localized burn (pinpoint radiation delivery) and a variety of less toxic and more effective chemical as well as biological therapies. The emerging paradigm is founded on such innovative therapies as antibody drugs, vaccines, angiogenesis inhibitors, and gene-based therapies. These innovative therapies could dramatically improve the control of cancer, causing less harm and offering patients the prospect of a more normal, higher quality life.
Most of the innovative anti-cancer therapies are being developed by biopharmaceutical companies, whose powerful ability to translate knowledge into medicine is creating robust and exciting product pipelines. Some of these drugs have been approved by the FDA and are being well received by the oncology community. Many others are approaching the regulatory and development finish line.
The Stephens Inc. Anti-Cancer Biopharmaceutical Investment Conference is the first of its kind and offers institutional investors the opportunity to see about 40 dynamic anti-cancer biopharmaceutical companies in one place and to learn in-depth about this dynamic, new industry firsthand.
Contact Sandy Kearney (800) 643-9691; (501) 377-2358 skearney@stephens.com
Conference Registration | Hotel Information
Company Profiles | Conference Schedule
Companies Listed In Alphabetical Order
Abgenix, Inc. ABGX abgenix.com
AEterna Laboratories, Inc. ALEA aeterna.com
Allos Therapeutics, Inc. ATH allos.com
AltaRex Corp. ALRXF altarex.com
Antigenics Inc. AGEN antigenics.com
Aphton Corporation APHT aphton.com
AVAX Technologies, Inc. AVXT avax-tech.com
AVI BioPharma, Inc. AVII antivirals.com
Biomira Inc. BIOM biomira.com
Celgene Corporation CELG celgene.com
Cell Genesys, Inc. CEGE cellgenesys.com
Cell Pathways, Inc. CLPA cellpathways.com
Cell Therapeutics, Inc. CTIC cticseattle.com
Corixa Corporation CRXA corixa.com
Coulter Pharmaceutical CLTR coulterpharm.com
CYTOGEN Corporation CYTO cytogen.com
Dendreon Corporation DNDN dendreon.com
EntreMed, Inc. ENMD entremed.com
Genta Incorporated GNTA genta.com
Genzyme Molecular Oncology GZMO genzyme.com
Geron Corporation GERN geron.com
IDEC Pharmaceuticals Corp.
IDPH idecpharm.com
ILEX Oncology, Inc.(1) ILXO ilexoncology.com
Imclone Systems Incorporated IMCL imclone.com
ImmunoGen, Inc. IMGN immunogen.com
Magainin Pharmceuticals, Inc. MAGN magainin.com
Matrix Pharmaceutical, Inc. MATX matx.com
Maxim Pharmaceuticals, Inc. MAXM maxim.com
Medarex, Inc. MEDX medarex.com
MedImmune, Inc. MEDI medimmune.com
MGI PHARMA, Inc. MOGN mgipharma.com
NeoRX Corporation(1) NERX neorx.com
Onyx Pharmaceuticals, Inc. ONXX onyx-pharm.com
OSI Pharmaceuticals OSIP osip.com
Pharmacyclics, Inc. PCYC pcyc.com
Protein Design Labs, Inc. PDLI pdl.com
Ribozyme Pharmaceuticals, Inc. RZYM rpi.com
Sangamo BioSciences, Inc.(1)(2)(3) SGMO sangamo.com
SuperGen Inc.(1) SUPG supergen.com
Targeted Genetics Corporation TGEN targetedgenetics.com
Techniclone Corporation TCLN techniclone.com
Titan Pharmaceuticals TTP titanpharm.com
Tularik Inc. TLRK tularik.com
Valentis, Inc. VLTS valentis.com
Vertex Pharmaceuticals VRTX vpharm.com
Vion Pharmaceuticals Inc. VION vionpharm.com
ZYCOS Inc.(4) PRIVATE |
